Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Abeona Therapeutics (ABEO) over the last 14 years, with Dec 2024 value amounting to $6.6 million.

  • Abeona Therapeutics' Share-based Compensation rose 49.06% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 64.46%. This contributed to the annual value of $6.6 million for FY2024, which is 39.01% up from last year.
  • Per Abeona Therapeutics' latest filing, its Share-based Compensation stood at $6.6 million for FY2024, which was up 39.01% from $4.8 million recorded in FY2023.
  • Abeona Therapeutics' 5-year Share-based Compensation high stood at $8.9 million for FY2021, and its period low was $3.1 million during FY2022.
  • For the 3-year period, Abeona Therapeutics' Share-based Compensation averaged around $4.8 million, with its median value being $4.8 million (2023).
  • In the last 5 years, Abeona Therapeutics' Share-based Compensation plummeted by 65.78% in 2022 and then surged by 56.28% in 2023.
  • Yearly analysis of 5 years shows Abeona Therapeutics' Share-based Compensation stood at $5.9 million in 2020, then skyrocketed by 52.33% to $8.9 million in 2021, then crashed by 65.78% to $3.1 million in 2022, then spiked by 56.28% to $4.8 million in 2023, then soared by 39.01% to $6.6 million in 2024.